D1-receptor regulation of synaptic potentials in the ventral tegmental area after chronic drug treatment.
Fiorillo
C D
CD
Vollum Institute, Oregon Health Sciences University, Portland 97201, USA.
Williams
J T
JT
Bonci
A
A
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology*; D004298:Dopamine / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology; D006168:Guinea Pigs; D066298:In Vitro Techniques; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence / Q000503:physiopathology; D058915:Purinergic P1 Receptor Antagonists; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D018080:Receptors, GABA-B / Q000187:drug effects / Q000502:physiology; D018047:Receptors, Purinergic P1 / Q000502:physiology; D019966:Substance-Related Disorders / Q000503:physiopathology*; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology; D013681:Tegmentum Mesencephali / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology
D001552:Benzazepines; D018491:Dopamine Agonists; D058915:Purinergic P1 Receptor Antagonists; D017447:Receptors, Dopamine D1; D018080:Receptors, GABA-B; D018047:Receptors, Purinergic P1; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D009020:Morphine; C071262:SK&F 82958; D003042:Cocaine; D004298:Dopamine